Abstract We identified a potential novel site of action for nicotine (NIC) since (a) systemic injection of NIC led to a dose-dependent decrease in the amplitude of the sleep state-dependent, vertex-recorded, P13 midlatency auditory evoked potential (generated by the reticular activating system, RAS), (b) localized injections of a nicotinic receptor antagonist into the pedunculopontine nucleus (PPN, the cholinergic arm of the RAS) blocked the effects of systemic NIC on the P13 potential (a measure of level of arousal), and (c) localized injection of a nicotinic receptor agonist into the PPN also led to a decrease in the amplitude of the P13 potential, an effect blocked by PPN injection of a nicotinic receptor antagonist. There were minor changes in the manifestation of the startle response (SR) at the concentrations used; however, NIC did decrease the hippocampal N40 potential, although its effects were not affected by antagonist or agonist injections into the PPN. These results suggest a potential mechanism underlying the anxiolytic effects of NIC-suppression of the cholinergic arm of the RAS.
Introduction
Nicotinic receptors in the brain underlie diverse neuronal activities, from the enhancement of learning and memory to addiction and neuroprotection (Dajas-Bailador and Wonnacott 2004) . Dysfunction of nicotinic receptors has been linked to a number of human diseases such as schizophrenia, Alzheimer's and Parkinson's diseases (Hogg et al 2003) . For example, patients with schizophrenia are often heavy users of nicotine (NIC) (reviewed in Goff et al 1992) . Such observations led to the suggestion that persons suffering from schizophrenia may be using NIC as a form of self-medication, thereby reducing the severity of their symptoms (Adler et al 1993; Gopalaswamy and Morgan 1986) . While the exact target site(s) of NIC's action that produce these effects are unknown, it has been shown that smoking normalizes a decrement in habituation to repetitive auditory stimuli that is believed to participate in a sensory gating deficit in these patients Braff 1993) . This deficit in sensory gating is believed to underlie the inability of schizophrenics to screen out irrelevant environmental stimuli (Freedman et al 1987) . While the neurological mechanisms underlying this deficit are not fully elucidated, it has been demonstrated that, in schizophrenic patients, the sleep state-dependent P50 midlatency auditory evoked potential does not habituate as efficiently as it does in unaffected individuals . These deficits in auditory processing have been observed in the majority of schizophrenics and in over half of their first-degree relatives (Freedman et al. 1987) .
Responses similar to the human P50 potential have been demonstrated in other animals including cats (wave ''A'') (Buchwald et al 1981) , and rats (Miyazato et al 1995) . In the rat, presentation of appropriate auditory stimuli elicits a positive polarity (like the P50 potential) evoked potential at a 13 ms latency. The P13 potential in the rat, like wave ''A'' in the cat (Harrison et al 1990) , is thought to originate in the pedunculopontine nucleus (PPN) , and has the same characteristics as the human P50 potential (Buchwald et al 1991; Buchwald 1986a, 1986b) , namely, (1) sleep state-dependence (present in waking and REM sleep, absent in slow wave sleep: only present during cortical desynchronization), (2) rapid habituation (indicative of a low synaptic security pathway), and (3) blockade by scopolamine (mediated by cholinergic neurons) (Miyazato et al. 1995 (Miyazato et al. , 1999b . In addition, injections locally into the PPN of neuroactive agents known to inhibit cholinergic PPN neurons are known to block the manifestation of the vertex-recorded P13 potential (Miyazato et al 1999a (Miyazato et al , 2000a . This evidence suggests that the P13 potential reflects outputs of the PPN, and is the rodent equivalent of the human P50 potential (GarciaRill and Skinner 2002) .
The present studies employed P13 potential recordings to determine the effects of NIC administered systemically, and whether these effects could be modulated by intracranial injections into the region of the PPN of a nicotinic agonist and antagonist. We also monitored the startle response (SR), since it is a descending arousal postural response modulated by PPN outputs (Koch et al 1993) , and the N40 potential, a waveform localized to the hippocampus and useful for measuring higherlevel sensory gating (Luntz-Liebman et al 1992) . However, the N40 potential is not sleep state-dependent (Miyazato et al 1995) , is the opposite polarity, and has too long a latency to be the equivalent of the human P50 potential (Garcia-Rill and Skinner 2002). Preliminary results have been presented in abstract form (Mamiya et al 2003 (Mamiya et al , 2004 .
Materials and methods
The methods employed have been previously published (Miyazato et al 1995 (Miyazato et al , 1998 (Miyazato et al , 1999a (Miyazato et al , 1999b (Miyazato et al , 1999c (Miyazato et al , 2000a . Adult male Sasco) were anesthetized with ketamine HCl (60 mg/kg, intramuscularly) and sodium pentobarbital (20 mg/kg, intraperitoneally). Anesthetic levels were maintained such that the withdrawal reflex to paw pinch was absent during surgical procedures. The animal was placed in a stereotaxic frame using hollow ear bars, which protected the middle ear from injury. After reflection of the scalp, stainless steel screws for recording auditory evoked potentials were inserted epidurally at the vertex (Vx), 5.5 mm anterior to the interaural line, 1.0 mm lateral to the midline, bilaterally. Averages were routinely collected from both Vx electrodes, but only the left side was used for analysis. None of the electrodes became unusable, so that the back-up right Vx electrodes were not used in this group of animals. Bilateral guide cannulae were implanted stereotaxically 2 mm dorsal to the PPN (A: 1.0, L: 1.9, H: 3.0) (Paxinos and Watson 1998) , in order to make intracranial PPN injections (0.1 ll each) using injectors (2 mm longer than the guide cannulae) inserted through the guide cannulae. Pairs of wires were inserted into the dorsal nuchal muscles bilaterally to monitor electromyographic (EMG) signals. A reference screw electrode was inserted into the frontal sinus. The screws were connected to a receptacle anchored to the skull, Penicillin G was given i.m., and the animals placed in a warm environment during recovery. Rats were housed individually in a vivarium with 12:12 light/dark schedule (lights on at 0600 h) and food and water ad libitum. Recordings began after a two-week recovery period. No more than one systemic or intracranial injection per week was performed on each animal, and no more than five injections of neuroactive agents were performed on each animal.
Auditory evoked potentials were recorded from the Vx of unrestrained, alert rats placed in a sound-attenuating chamber (60·60·60 cm). Earphones were mounted on opposite sides of the recording chamber centered 10.6 cm above the floor to create a diffuse sound field within the chamber. A diffuse sound field is desired because the rats are free to move within the chamber. Input to the earphones consisting of 100 ls rectangular pulses was provided by a Grass Inst. Click-Tone Stimulator (Model S10CTCM). Measurements of the stimulus were made using a Larson-Davis Sound Level analyzer, model 824. The microphone of the sound analyzer was placed at the level of the rat and measurements were made with the chamber door closed. Measurements of single click stimuli presented at a rate of 1 Hz showed a maximum of 97.7 dB SPL in the center of the chamber using a peak level measurement mode. At various points around the periphery of the chamber, the stimulus differed by no more than 6.6 dB SPL below the maximum level. It is worth noting that the spectrum of the clicks measured in the sound field created emphasized the higher frequencies. Within the relatively small confines of the test chamber, an essentially diffuse sound field was created.
The threshold of the P13 potential is about 70 dB SPL (Miyazato et al 1995 (Miyazato et al , 1998 (Miyazato et al , 1999a . Measurements made using the impulse measurement mode were assumed to best characterize the click stimuli employed. This measure, more conservative than the simpler and more common peak SPL, integrates the power using a 35-ms time constant, thereby better representing the effective level of the stimulus. Employing the instrumentation described and the conditions under which the animals were tested, the stimuli created using two 0.1 ms pulses with an interpulse interval of 1 ms was 3.4 dB greater than sounds created by a single pulse. Such closely spaced pulses generated a perceived single click-like sound, reflecting the limits of temporal resolution and the transducer's power integration over the two pulses. Indeed, the overall duration of the acoustic signal generated by two pulses was found to be about 2 ms. However, the animal's percept is speculative, so the two-pulse stimulus used, and perceived as a single click-like sound, will be referred to as one stimulus.
A constant broadband noise background (49.7 dB SPL measured at the center of chamber) was provided by a 10-cm diameter fan. The chamber was lit by a 12-V DC bulb and a window and peep hole viewer allowed undetected observation of the animal. Wires from the swivel commutator were connected to a plug that mated with the receptacle implanted on the animal. Following a 15-min acclimation period in the chamber, auditory evoked responses were recorded during quiet waking, judged from constant observation of the animal's behavior, EEG and EMG. All subjects were only tested between 0900 h and 1300 h to control for possible time of day effects.
Evoked potentials from the Vx were amplified (10,000·) and bandpass filtered at 3 Hz-1 kHz. The EMG signal was amplified (10,000·), filtered at 30 Hz-3 kHz and rectified. All recordings were amplified using Grass Inst. (Quincy, MA, USA) model P511 amplifiers and digitized at a rate of 10 kHz, averaged, stored on computer disks, and analyzed using SuperScope software (GW Inst., Summerville, MA, USA). Measurement of the amplitude of the P13 auditory evoked potential, a positive waveform starting at a latency of 7-9 ms and peaking at 12-14 ms (Miyazato et al 1995 (Miyazato et al , 1998 (Miyazato et al , 1999a (Miyazato et al , 1999b (Miyazato et al , 1999c (Miyazato et al , 2000a , was made from the beginning of the wave to its peak. The longer latency N40 potential was measured as previously described, as was the SR following rectification of the EMG (Miyazato et al 1995 (Miyazato et al , 1998 . Each stimulus, as described above, consisted of two rarefaction clicks, 0.1 ms duration each at an interval of 1 ms (total duration of each stimulus about 2 ms). Each trial consisted of pairs of stimuli presented at an interstimulus interval (ISI) of 500 ms, with an intertrial interval of 5 s, until 32 pairs of evoked potentials were acquired for averaging. The amplitudes of the P13 potential, the N40 potential and the SR were determined as the amplitude of the response following the first stimulus, while habituation was expressed as the amplitude of the potential induced by the second stimulus as a percent of the amplitude of the potential induced by the first stimulus.
The protocol used included control recordings carried out before any procedure. We also recorded saline controls immediately after injection of saline i.p. and every 10 min for 60 min. These results were compared to those obtained at each time point following drug administration. First, systemic injections of NIC at one of four concentrations (0.3, 0.6, 1.0 and 2.5 mg/kg), were administered in random order to derive a doseresponse curve for NIC (n=8 rats). In a different group of animals (n=8), we tested the effects of intracranial PPN injections (0.1 ll in volume) of the nicotinic agonist dimethylphenylpiperazinium (DMPP), which does not lead to desensitization of nicotinic receptors, at one of three concentrations (1, 5 and 12.5 nM), administered at random to derive a dose-response curve for this nicotinic agonist. In another group of animals (n=8), we pretreated using the nicotinic receptor antagonist mecamylamine (MEC), injected intracranially at one of three concentrations (0.1 ll in volume at 10, 30 or 100 nM), administered at random and made three recordings to make sure that this agent did not have a significant effect on the measures used. We then injected NIC (0.6 mg/kg, a previously determined effective dose) to determine the dose-response relationship of the blockade of the effects of systemic NIC administration by pre-treatment with MEC intracranially. In the last group (n=8), we used intracranial pre-treatment with MEC (100 nM, previously determined to effectively block systemic NIC administration) to determine its ability to block the previously determined effects of intracranial DMPP (12.5 nM).
At the end of the recording sessions, each rat received either an injection of 0.1 ll of Fast Green (to determine injection spread) or a 0.5 mA/2 s electrolytic lesion at the injection site. The animals received an overdose of barbiturates and were perfused with formaldehyde, the brains cut at 50 lm, and sections processed for NADPH diaphorase histochemistry as previously described (Miyazato et al 1995 (Miyazato et al , 1998 (Miyazato et al , 1999a (Miyazato et al , 1999b (Miyazato et al , 1999c (Miyazato et al , 2000a . Only animals in which the injection or lesion was localized to the region of NADPH diaphorase positive PPN neurons were used in the analysis.
Results were evaluated using two-factor repeatedmeasures analysis of variance (ANOVA) and main effects were followed with post hoc contrasts using a Newman-Keuls test, via GB-Stat software. Additionally, the data did not suggest that normal distribution assumption was violated, namely the test for non-normality of the residuals. The Kolmogorov-Smirnov test for normality on the residuals was not significant (P=0.36), leading to the conclusion that the data did not suggest a departure from the normal distribution. All animal procedures were approved by the Institutional Animal Care and Use Committee.
Results

P13 potential results
(a) Systemic NIC (n=8) Figure 1A shows representative recordings of the P13 potential, N40 potential and SR following systemic injections of either saline or NIC. Note the reduction of the response after the first stimulus following NIC but not saline. [The use of the paired stimulus paradigm allowed calculation of the response elicited by the first stimulus (initial activation of the system), and of the habituation of the system to repetitive stimuli (ratio of the second response, 500 ms after, to the first response) (not shown).]. Figure 1B shows the mean and standard error of the amplitude of the P13 potential after the first stimulus following systemic administration of NIC at 0.3 mg/kg (crosses), 0.6 mg/kg (filled circles), 1.0 mg/kg (filled squares) and 2.5 mg/kg (filled triangles), compared to systemic injection of saline (open circles). Two-way repeated measures ANOVA comparing saline vs each concentration of NIC revealed statistically significant decreases in P13 potential amplitude between saline and 0.6 mg/kg (F=7.20, P<0.01) at 0 and 10 min; between saline and 1.0 mg/kg (F=5.63, P<0.01) at 0 and 10 min; and between saline and 2.5 mg/kg (F=12.95, P<0.01 at 0-40 min, P<0.05 at 50 min) at all time points except 60 min.
There were no statistically significant differences between saline and NIC at any concentration on the percent habituation (ratio of the two responses 500 ms apart), due to the variability in percent habituation. This suggests that NIC has an inhibitory effect on the initial activation of the system (amplitude), but not on habituation to repetitive stimuli.
(b) Intracranial DMPP (n=8) Figure 2A shows representative recordings of the P13 potential, N40 potential and SR following injection of either saline or DMPP, the nicotinic receptor agonist. Note the decrement in amplitude following DMPP injection into the PPN compared to the lack of significant effect following saline injection into the PPN. Figure 2B shows the mean and standard error of the amplitude of the P13 potential after the first stimulus following intracranial (PPN) administration of DMPP at 1.0 nM (open squares), 5.0 nM (· symbols), and 12.5 nM (filled diamonds), compared to PPN injection of saline (open circles). Twoway repeated-measures ANOVA comparing saline versus each concentration of DMPP revealed no statistically significant decreases in P13 potential amplitude between saline and 1.0 or 5.0 nM DMPP (F=0.04, ns) [but showed a significant difference using 5.0 nM DMPP at a single time point, 10 min, when using a one-way repeated-measures ANOVA (P<0.05)] comparing the pre-injection control, not saline, and the post-injection amplitudes; and between saline and 12.5 nM DMPP (two-way ANOVA, F=5.19, P<0.01) at all time points vertical 50 lV, horizontal 10 ms. Note the presence of the P13 potential in the control (filled circle) and the reduction in amplitude after NIC (open circle). The N40 potential was also reduced in amplitude, as was the SR (bottom recordings in each condition). B Mean amplitude of the P13 potential in eight rats recorded before injection (Ctl), immediately after injection (0 min) and every 10 min for 1 h. Averages after saline (open circles), NIC at 0.3 mg/kg (crosses), NIC at 0.6 mg/kg (filled circles), NIC at 1.0 mg/kg (filled squares) and NIC at 2.5 mg/kg (filled triangles). Note the significant (double asterisks at P<0.01) decreases in amplitude of the P13 potential at 0 and 10 min after 0.6 mg/kg and 1.0 mg/kg, and at 0-30 min after 2.5 mg/kg except 10 min. There were no statistically significant changes in P13 potential habituation following intracranial DMPP compared to intracranial saline.
(c) Intracranial MEC + NIC (n=8) Figure 3A shows the mean and standard error of the amplitude of the P13 potential after the first stimulus following intracranial (PPN) pre-treatment with MEC at 10 nM (open diamonds), 30 nM (open squares), and 100 nM (open triangles), followed by systemic injection of NIC (0.6 mg/kg), compared to injection of saline (open circles). Two-way repeated-measures ANOVA comparing saline versus each concentration of DMPP revealed no statistically significant decreases in P13 potential amplitude between saline and any concentration of MEC (so MEC did not directly affect P13 potential amplitude). The closed circles denote the effects of 0.6 mg/kg of systemic NIC without pre-treatment with MEC, in other words significant decreases in P13 potential amplitude at 0, 10 and 30 min.
Pre-treatment with 10 nM MEC failed to affect the NIC-induced decrease in P13 potential amplitude only at 0 min (F=2.20, P<0.05). However, pre-treatment with 30 nM (F=0.50, ns) or 100 nM (F=2.14, ns) MEC injection into the PPN blocked the decrement in P13 potential amplitude induced by systemic NIC administration. There were no statistically significant changes in P13 potential habituation following intracranial MEC compared to intracranial saline, or following systemic NIC administration. Figure 3B shows the mean and standard error of the amplitude of the P13 potential after the first stimulus following intracranial (PPN) pre-treatment with MEC at 100 nM (filled triangles), followed by PPN injection of DMPP at 12.5 nM, compared to PPN injection of saline (open circles), or to PPN injection of DMPP at 12.5 nM but without pre-treatment with MEC. The decrease in P13 potential amplitude induced by PPN injection of DMPP at 12.5 nM (filled diamonds) at all time points except 10 min (F=5.19, P<0.01 at 0, 20, 50, 60 min and P<0.05 at 30, 40 min) was blocked by pre-treatment with MEC at 100 nM (filled triangles), and was similar to the effects of PPN injections of saline (open circles) (F=0.13, ns).
Startle response results Figure 4 shows all of the results obtained on the SR. Figure 4A shows the dose-response relationship between the four concentrations of systemically administered NIC and SR amplitude. There were no statistically significant effects following 0.3, 0.6 or 1.0 mg/kg. NIC at 2.5 mg/kg induced significant decreases in SR amplitude at 0, 10, 20 and 30 min (F=28.56, P<0.01), and at 40 min (P<0.05). The effects of systemically administered NIC were not paralleled by PPN injections of DMPP at the concentrations used. Figure 4B shows that the nicotinic antagonist MEC had no effect on SR amplitude when injected by itself into the PPN. Using the 0.6 mg/kg concentration of NIC, which had led to a decrease in P13 potential amplitude but not SR amplitude, the effects of MEC pre-treatment into the PPN had no effect on subsequent systemic NIC on SR amplitude, as expected. Figure 4C shows that there were no statistically significant differences in SR amplitude following 1, 5 or 12.5 nM injections of DMPP into the PPN. Fig. 4D shows that, since DMPP at the concentrations used had no effect on SR amplitude, the effects of MEC pre-treatment into the PPN had no effect (after PPN injection of DMPP) on SR amplitude. There were no significant changes in SR habituation following any treatment. . There were no differences between these injections compared to Ctl at 0-20 min. Treatment with only NIC at 0.6 mg/kg, shown as filled circles (similar results as in Fig. 1b) , induced significant P13 potential decreases in amplitude at 0, 10 and 30 min. Note that NIC treatment was completely blocked by pre-treatment with 100 and 30 nM MEC, but 10 nM MEC showed a significant difference after NIC, but at * P<0.05 at time 0 min only (n=8). B Pre-treatment with MEC using 100 nM (filled triangles) compared to saline (open circles). There were no differences between these injections compared to Ctl at 0-60 min. Treatment with only DMPP at 12.5 nM, shown as filled diamonds (similar results to those in Fig. 2b ), induced significant P13 potential decreases in amplitude at 0, and 20-60 min. Note that DMPP treatment was completely blocked by pre-treatment with 100 nM MEC (filled triangles) (n=8) N40 results Figure 5 shows all of the results obtained on the N40 potential. Figure 5A shows the dose-response relationship between the four concentrations of systemically administered NIC and N40 amplitude. The N40 potential was not suppressed significantly by 0.3 mg/kg systemic NIC at 50 min, but all other concentrations decreased N40 amplitude for most of the 60 min recording period (0.6 mg/kg, F=7.98, P<0.01; 1.0 mg/ kg, F=4.96, P<0.01; 2.5 mg/kg, F=7.57, P<0.01). Figure 5B shows that pre-treatment with MEC into the PPN generally did not affect the systemic NIC administration effect on N40 amplitude (although some points were not significantly different from saline, there were no differences compared to NIC, and N40 amplitude was still decreased by NIC even with MEC pre-treatment). Fig. 5C shows that localized injections of DMPP into the PPN failed to affect N40 amplitude (F=0.74, ns) , despite the decrement induced in P13 amplitude (see Fig. 2 ). Finally, Fig. 5D shows pre-treatment with DMPP into the PPN did not affect N40 amplitude, nor did pre-treatment with MEC followed by treatment with DMPP (although this combination did show decreases compared to saline, there were no differences compared to DMPP alone). There were no significant changes in N40 habituation following any treatment.
Discussion
The present results provide new evidence suggesting that one of the sites of action of NIC may be in the reticular activating system (RAS), specifically, on PPN neurons. This is an important finding since the PPN is the cholinergic arm of the RAS and is known to play a role in controlling sleep-wake states (Datta and Siwek 2002) . The PPN is active during waking and REM sleep (Datta 1995) ; in other words it is most active during synchronization of fast cortical rhythms (Steriade et al 1996) . Systemic injections of NIC, as well as intracranial injections of the nicotinic agonist DMPP into the PPN, were both found to decrease the amplitude of the P13 potential. The P13 potential is sleep state-dependent, being present when PPN activity is highest (waking and REM sleep), during synchronization of high frequency cortical rhythms (Miyazato et al 1995 (Miyazato et al , 1999c . This suggests that NIC may act to inhibit the net activity of the cholinergic arm of the RAS, thus having a calming or anxiolytic effect, at least initially. Some clinical implications of this observation will be discussed below.
The P13 potential
Before we discuss the implications of the calming effect of NIC, we must first answer the following question: is the P13 potential mediated by the PPN? A series of consistent and well-controlled studies has established that (a) the P13 potential is sleep state-dependent, being present when PPN cells are most active, (b) the P13 potential is blocked by low doses of the cholinergic antagonist scopolamine, so that it is generated in part by muscarinic projections, and (c) the P13 potential habituates rapidly, indicating it is generated by a low synaptic security pathway such as the RAS (Miyazato et al 1995 (Miyazato et al , 1998 (Miyazato et al , 2000 . Furthermore, injections into the PPN of neuroactive agents that are known to inhibit PPN neurons also lead to a dose-dependent decrease in the amplitude of the Vx-recorded P13 potential (Miyazato et al 1999a (Miyazato et al , 2000a , suggesting that the Vx-recorded waveform is modulated by neurons in the vicinity of the injections. Finally, interventions which modulate waking and arousal, such as anesthetics, ethanol and head injury, all lead to a decrease in P13 potential amplitude, and the level of recovery of P13 potential amplitude is related to the level of arousal (Miyazato et al 1999c) . , NIC at 0.3 mg/kg (crosses), NIC at 0.6 mg/kg (filled circles), NIC at 1.0 mg/kg (filled squares) and NIC at 2.5 mg/kg (filled triangles). Note the significant (double asterisks at P<0.01 or single asterisk P<0.05) decreases in amplitude of the N40 potential at 0-60 min after 0.6 mg/kg, 0-40 min after 1.0 mg/kg, and 0-60 min after 2.5 mg/kg. Compare the greater decreases in N40 potential to those of the P13 potential (Fig. 1b) . B Pre-treatment with MEC using 10 nM (open diamonds), 30 nM (open squares) or 100 nM (open triangles), compared to saline (open circles). Treatment only with NIC at 0.6 mg/ kg is shown as filled circles, induced significant N40 potential decreases in amplitude at 0-20 and 50 min. Note that NIC treatment was not blocked by pre-treatment with 10, 30 or100 nM MEC (not different from NIC at 0.6 mg.kg). C Mean amplitude of the N40 potential in eight rats recorded before injection (Ctl), immediately after injection (0 min) and every 10 min for 1 h. Averages after saline (open circles), DMPP at 1.0 nM (x symbols), DMPP at 5.0 nM (asterisks), and DMPP at 12.5 nM (filled diamonds). There were no significant changes in N40 potential amplitude after DMPP injections into the PPN. D Pre-treatment with MEC using 100 nM (filled triangles) compared to saline (open circles). There were no differences between these injections compared to Ctl except at 10, 50 and 60 min. Treatment with only DMPP at 12.5 nM, shown as filled diamonds, induced no significant changes in N40 potential amplitude at 0-60 min b Fig. 4A -D Effects on the SR. A Mean amplitude of the SR in eight rats recorded before systemic injection (Ctl), immediately after injection (0 min) and every 10 min for 1 h. Averages after saline (open circles), NIC at 0.3 mg/kg (crosses), NIC at 0.6 mg/kg (filled circles), NIC at 1.0 mg/kg (filled squares) and NIC at 2.5 mg/kg (filled triangles). Note the significant (double asterisks at P<0.01 or single asterisk P<0.05) decreases in amplitude of the SR at 0-40 min after 2.5 mg/kg. B Pre-treatment with MEC using 10 nM (open diamonds), 30 nM (open squares) or 100 nM (open triangles), compared to saline (open circles). There were no differences between these injections compared to Ctl at 0-20 min. Treatment with only NIC at 0.6 mg/kg, shown as filled circles, induced significant SR decreases in amplitude at 10 min and 20 min. Note that NIC treatment was completely blocked by pre-treatment with 100 nM MEC, but 10 and 30 nM MEC showed a significant difference after NIC but at * P<0.05 at 10 min for 10 nM and at 20 min for 30 nM MEC. C Mean amplitude of the SR in eight rats recorded before injection (Ctl), immediately after injection (0 min) and every 10 min for 1 h. Averages after saline (open circles), DMPP at 1.0 nM (· symbols), DMPP at 5.0 nM (asterisks), and DMPP at 12.5 nM (filled diamonds). There were no significant changes in SR amplitude after DMPP injections into the PPN. D Pre-treatment with MEC using 100 nM (filled triangles) compared to saline (open circles). There were no differences between these injections compared to Ctl at 0-60 min. Treatment with only DMPP at 12.5 nM, shown as filled diamonds, induced no significant changes in SR amplitude at 0-60 min b A second critical question is: are there nicotinic receptors in the PPN? The most common nicotinic receptors (pentameric conductance channels for calcium, potassium and sodium) in the brain are a-bungarotoxin insensitive receptors made up of heteromeric a-4 and b-2 subunits, and a-bungarotoxin-sensitive a-7 homomeric receptors (Lukas et al 1999) . The former account for most of the high affinity nicotinic receptors in the brain, and the latter for the low affinity binding of NIC (Lukas et al 1999) . The PPN is known to contain neurons that express NIC-sensitive acetylcholine receptors with MEC-sensitive a-4 subunits (Tribollet et al 2004) . MEC is thought to block most nicotinic receptors except a-7 receptors (Freedman et al 1994; Papke et al 2001) , although at higher concentrations MEC can block a-7 receptors as well (Papke et al 2001) . Intracellular recordings from PPN neurons have shown that nicotinic receptor agonists directly (in the presence of tetrodotoxin) depolarize these cells early in development but then hyperpolarize PPN neurons as the animal matures (Good et al 2004) . Our results are consistent with these observations, showing that NIC-induced decrements in P13 potential amplitude had short latency (within minutes) and were fairly short lasting (<20 min) at concentrations of NIC similar to those attained by heavy smokers, for example 0.6 mg/kg (Fig. 1B) .
A number of experimental limits should be noted when considering these results. First, the use of systemic administration of NIC obviously activates a large number of brain sites. The effects on the measures undertaken (P13 potential, N40 potential, SR) are only a partial list of the potential processes affected by NIC, especially when administered systemically. Secondly, we should stress that the effects of NIC on arousal processes may be only the first phase of multiple effects on brain function. The results described suggest that the effects of NIC on the RAS may have fairly short latency and duration, so that other consequences, including longer latency effects and reinforcing mechanisms, may result from activation of different brain systems. Only acute administration was used, and no statements can be made about the effects of drug exposure on reinforcing or addictive consequences. The paradigm used (weekly injections of four different concentrations administered randomly, plus saline: five injections total) would not be expected to have such consequences.
To determine if the effects of systemic NIC administration on the P13 potential were mediated by the PPN, we used intracranial injections of the non-desensitizing nicotinic receptor agonist DMPP (Phelan and Gallagher 1992) . DMPP induced a short latency (similar to NIC), but, probably due to its non-desensitizing properties, long-lasting (>30 min) inhibition of P13 potential amplitude when injected into the PPN at modest concentrations (12.5 nM) (Fig. 2B) . The similar inhibitory effects of systemic NIC and intracranial DMPP suggest that changes in P13 potential amplitude may be mediated by the PPN. A potential confounding factor is that NIC and the agonist DMPP are thought to act presynaptically to promote the release of other transmitters (Vizi and Lendvai 1999) , thereby inducing their effects via other inputs to PPN. Among these are known inhibitory actions on PPN cells by the release of GABA (Vazquez and Baghdoyan 2004) or nitric oxide (Datta et al 1997) . Thus, nicotinic receptors are located on both cell bodies and nerve terminals, and work by facilitating the release of other neurotransmitters, thought to be mediated by presynaptic actions, as well as by direct postsynaptic action (Benowitz 1996) . Our results indicate that the effects of systemic NIC and intracranial DMPP on the P13 potential were blocked by modest concentrations of MEC (10, 30 and 100 nM) (Fig. 3) . This suggests that the effects of NIC or DMPP on the P13 potential probably were produced by MEC-sensitive a-4 subunit containing receptors. However, we cannot be certain that such a blockade occurred at the level of presynaptic or postsynaptic sites. Moreover, we do not know whether NIC and/or DMPP acted on cholinergic and/or non-cholinergic PPN neurons, but can only estimate its net effect on the output of the PPN nucleus, as far as P13 potential manifestation allows.
The startle response
The PPN is also known to play a role in postural and locomotor systems, as well as in the modulation of sensory input (for a review see Reese et al 1995) . Cholinergic activation of pontine neurons is known to block habituation (not necessarily increase amplitude) of the SR (Fendt and Koch 1999) , and lesions of the PPN are known to release inhibition of the SR (Koch et al 1993) ; therefore it is important to determine if NIC has effects on descending PPN modulation of the SR. Previous studies using NIC have shown that NIC has a biphasic effect on SR amplitude, with increases at lower dosages than those used here, and decreases at higher doses comparable to those used here (Acri et al 1994) . Our results revealed that systemic NIC reduced SR amplitude only at the higher concentrations used (1.0 and 2.5 mg/kg), but were not statistically significant at lower concentrations. In general, then, our results confirm previous observations for higher doses: decrement in SR amplitude (Fig. 4A ). This suggests that nicotinic receptors inhibit both ascending (P13 potential) as well as descending (SR) PPN efferent modulation.
We should point out the differences between our SR paradigm and those used by others. First, we do not use whole-body movement to assess SR, but rather direct EMG recordings from neck muscles. Such recordings reveal that the SR, in keeping with the original demonstrations (Szabo 1965) , is actually composed of a triphasic response, (a) an initial excitation, (b) followed by a brief inhibition coincident with the P13 potential, and (c) then a long-lasting excitation (Miyazato et al 1995 (Miyazato et al , 1999b . It was the initial excitatory response that was measured in the present studies, but it is likely that it is the third phase that is responsible for the whole-body movements usually measured (Miyazato et al 1995 (Miyazato et al , 1999b . Another difference was in the auditory stimuli used. Most SR studies use long duration stimuli, usually high frequency tones, whereas we used the same click stimulus for eliciting auditory potentials and changes in neck EMG. Such stimulation is expected to induce only minor movement, allowing accurate recordings of the auditory evoked responses. However, such stimuli appear to induce changes only in the initial phase of the SR (see Fig. 1A ). Therefore, comparison with studies using whole-body assessment of SR may not be appropriate.
The N40 potential
The N40 potential is generated by the hippocampus, is modulated by cholinergic input (Stevens et al 1999) , and its manifestation is mediated by a-7 nicotinic receptors (Luntz-Liebman et al 1992) . While it is a useful measure of higher level sensory gating, it is not equivalent to the human P50 potential, being insensitive to the muscarinic antagonist scopolamine (Miyazato et al 1995) , having no sleep state-dependence (not arousal-related) and having the opposite polarity (Miyazato et al 1999b) , and too long a latency for the body size (Garcia-Rill and Skinner 2002). Our results do confirm the observed inhibition of the N40 potential by NIC (Stevens et al 1997) , which appears to undergo more significant suppression than the P13 potential at the same concentrations of NIC (compare Figs. 1B and 5A ). However, this effect was not modulated by intracranial injections into the PPN of either the nicotinic agonist DMPP, or the a-4-b-2 receptor antagonist MEC (Fig. 5B, C) . This result suggests that the manifestation of the P13 potential is not a prerequisite for the manifestation of the N40 potential. Given their physiological differences this is not surprising; however, no previous study has so clearly demonstrated that blockade of PPN output, which presumably induces a decrement in arousal level, does not affect N40 potential manifestation. This serves to emphasize the lack of arousal-related characteristics of the N40 potential, which is present during slow-wave sleep (during a state of sensory unconsciousness).
Habituation
Our results using a paired stimulus paradigm did not reveal significant changes in habituation of any of the measures undertaken. As previously suggested, this may be more a result of the decrement in the amplitude of the initial response rather than the ratio of the second response to the first (Miyazato et al 1999a) . That is, the marked decrement in the amplitude of the initial response, whether of the P13 potential, the N40 potential or the SR, induced by NIC or DMPP is likely to have also reduced the amplitude of the second response. This effectively creates a floor effect for assessing the actual inhibition due to repetitive stimulation. Previous studies have suggested that, if there is a transient decrement in the amplitude of the initial response, habituation of the second response may be underestimated, so that changes in habituation should not be considered accurate until the amplitude of the initial response has recovered (Miyazato et al 1999a) . In the present studies, there were no significant changes in habituation even after the initial response had achieved its control amplitude in any of the measures analyzed.
It should be noted that decreased habituation of any of these measures is evident in experimental or pathological conditions, not in normal animals. For example, deficits in sensory gating are evident in the P13 potential after immobilization stress (Miyazato et al 2000b) , and in the N40 potential in isolation-reared rats (O'Neill et al 2003) , cocaine-treated mice (Stevens et al 1999) , or inbred DBA mice (Stevens et al 1998) . The effects of NIC or DMPP, especially since they tend to suppress these potentials, would then not be expected to induce significant changes in habituation. Schizophrenia in humans is marked by increased output of the RAS (especially functions mediated by the PPN), including hypervigilance, increased REM sleep drive, decreased REM sleep latency and decreased slow-wave sleep (reviewed in Garcia-Rill 1997). A small percentage of intractable institutionalized schizophrenic patients were found to have increased PPN cell number in their brains upon post mortem analysis (Garcia-Rill et al 1995; Karson et al 1991) , although outpatient, more tractable patients, did not show such increases Manaye et al 1999) . Moreover, schizophrenic patients have been shown to have decreased habituation of the P50 potential , and this failure of habituation to repetitive stimuli can be transiently alleviated by NIC (Adler et al 1993) . Therefore, it is plausible that the use of NIC by these patients may initially suppress cholinergic RAS output. The present results provide a plausible explanation for the purported calming effects of NIC and its potential use as selfmedication.
